Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Parabilis Medicines, Inc.
parabilismed.comAI Executive Summary
AI-powered analysis of 8-K filing content
Parabilis Medicines secured a $75 million strategic investment from Regeneron Pharmaceuticals through a private placement of 4.17 million shares at a 10% discount to its $20 IPO price, closing concurrent with the company's IPO on June 11, 2026. This capital infusion strengthens Parabilis's financial position as it transitions to public markets.
Key Takeaways
Regeneron invested $75 million for 4,166,666 shares at $18 per share (90% of $20 IPO price), representing a significant strategic partnership
The private placement closed on June 11, 2026, concurrent with Parabilis's IPO, providing immediate capital for growth and development
2 more takeaways